Precigen Stock Climbs After Strong 1Q for Papzimeos Sales

Dow Jones05-15

By Dean Seal

Shares of Precigen jumped after the company said the first full quarter of sales for its flagship drug went better than expected.

The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date.

The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year.

The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet.

The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier.

Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 14, 2026 12:38 ET (16:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635814744?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635814744","market":"sh","top_or_hot":-1,"title":"Precigen Stock Climbs After Strong 1Q for Papzimeos Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> jumped after the company said the first full quarter of sales for its flagship drug went better than expected. \n</p>\n<p>\n  The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date. \n</p>\n<p>\n  The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year. \n</p>\n<p>\n  The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet. \n</p>\n<p>\n  The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 12:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Stock Climbs After Strong 1Q for Papzimeos Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Stock Climbs After Strong 1Q for Papzimeos Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 00:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> jumped after the company said the first full quarter of sales for its flagship drug went better than expected. \n</p>\n<p>\n  The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date. \n</p>\n<p>\n  The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year. \n</p>\n<p>\n  The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet. \n</p>\n<p>\n  The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier. \n</p>\n<p>\n  Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 12:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635814744","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635814744","pubTimestamp":1778776680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Precigen jumped after the company said the first full quarter of sales for its flagship drug went better than expected.The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date.The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year.The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet.The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier.Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"Papzimeos第一季度销售强劲后Precigen股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Precigen jumped after the company said the first full quarter of sales for its flagship drug went better than expected. \n\n\n  The stock gained 16% to $4.81 on Thursday, pushing shares back in positive territory year to date. \n\n\n  The biopharmaceutical company said its drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, had strong momentum through the first three months of the year. \n\n\n  The treatment generated $21.6 million in product revenue. Total company revenue jumped to $23.3 million from $1.3 million, ahead of analyst targets for $20.8 million, according to FactSet. \n\n\n  The big jump in revenue allowed Precigen to shrink its quarterly loss to $7.9 million, or 2 cents a share, from $54.2 million, or 18 cents a share, in the same quarter a year earlier. \n\n\n  Given the cash inflows and anticipated revenue ahead, Precigen expects to break even on cash flow by the end of this year, it said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 12:38 ET (16:38 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635814744","isCrawlerRequest":true}